TRINETRA › Sectors › Healthcare
Strides Pharma Science Limited (STAR) — share price, P/E and fundamentals
Strides Pharma Science Limited (NSE: STAR) closed at ₹1,068.80 on 30 Oct 2026, +33.8% over one year, against a 52-week range of ₹768.65 – ₹1,260.90.
In the quarter ended 30 Sept 2026 (consolidated, filed 29 Oct 2026) it reported revenue of ₹1,430 cr and net profit of ₹131 cr, a 9.2% net margin; revenue grew 17.1% and profit fell 3.0% year on year.
On four consecutive filed quarters its trailing P/E is 16.0; since 22 May 2025 its own P/E has ranged from 14.3 to 22.4 (median 18.8), and today's reading is higher than 17% of those 356 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 15.3%, ROCE 18.0%, debt-to-equity 0.54, Piotroski F-score 7 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 22% of 63 sector peers; PBT margin higher than 16% of 63 sector peers; ROE higher than 59% of 63 sector peers.
Key figures
| Last close | ₹1,068.80 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -11.1% / +0.2% / +33.8% |
| 52-week low – high | ₹768.65 – ₹1,260.90 |
| Market capitalisation | ₹9,851 cr |
| Trailing P/E | 16.0 |
| Price / book | 2.88 |
| EV / EBITDA | 10.2 |
| Earnings yield | 6.3% |
| TTM EPS | ₹66.92 |
| TTM net profit | ₹617 cr |
| Quarter revenue | ₹1,430 cr |
| Quarter net profit | ₹131 cr |
| Net margin | 9.2% |
| Revenue growth (YoY) | +17.1% |
| Profit growth (YoY) | -3.0% |
| Return on equity | 15.3% |
| ROCE | 18.0% |
| Debt / equity | 0.54 |
| Current ratio | 1.29 |
| Free cash flow | ₹-160 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹23.1 cr |
Against Healthcare peers
| Metric | STAR | Peer median | Percentile |
|---|---|---|---|
| Net margin | 9.15 | 12.89 | 22 |
| PBT margin | 10.46 | 17.68 | 16 |
| ROE | 15.32 | 13.86 | 59 |
| ROCE | 18.01 | 16.59 | 56 |
| Debt / equity | 0.54 | 0.11 | 89 |
| FCF margin | -5.93 | 2.08 | 29 |
| Cash conversion | 0.36 | 1.25 | 8 |
| Trailing P/E | 15.97 | 43.26 | 3 |
Questions
What is the P/E ratio of Strides Pharma Science Limited?
Strides Pharma Science Limited's trailing P/E is 16.0, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 22 May 2025 its P/E has ranged 14.3–22.4.
What were Strides Pharma Science Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Strides Pharma Science Limited reported revenue of ₹1,430 cr and net profit of ₹131 cr (consolidated), filed with the exchange on 29 Oct 2026.
What is Strides Pharma Science Limited's ROE?
Return on equity is 15.3% based on the balance sheet dated 30 Sept 2026.
Does Strides Pharma Science Limited have debt?
Debt-to-equity is 0.54 on the balance sheet dated 30 Sept 2026.
What is STAR's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, STAR traded between ₹768.65 and ₹1,260.90.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.